Pulse Biosciences replaces nearly exhausted ATM with new $85M equity facility

Pulse is a clinical-stage bioelectric-medicine company using Nano-Pulse Stimulation to advance nPulse systems in electrophysiology and soft-tissue ablation; its 2026 plan calls for completing NANOPULSE-AF IDE enrollment by early Q4.

The filing mainly preserves financing access, rather than delivering cash today. Pulse authorized a new Mizuho at-the-market program for up to $85 million. The company is not required to sell any shares, so this is borrowing capacity in equity form—not a committed $85 million financing.

The new facility is an expansion of an already-active funding strategy, not a surprise pivot. Pulse had already sold approximately $68.8 million of the prior $75 million Mizuho authorization by September 14. Replacing that nearly exhausted authorization with another $85 million makes the direction—funding ongoing clinical and product development—largely known; the new information is the size of the replacement capacity.

The business benefit is flexibility; the cost is potential dilution. The program lets Pulse raise capital opportunistically as it advances cardiac and soft-tissue programs, but every sale increases the share count and can fund operations only by issuing equity. The filing does not say that any of the new shares have been sold, and it provides no updated cash runway, so it improves optionality without yet changing the company’s operating resources.

Terminating the TD Cowen program is administrative consolidation, not a separate strategic event. Only up to $1.0 million remained available under that agreement when it was ended, while the new Mizuho program becomes the meaningful source of future ATM capacity.

Bottom line: Pulse has secured a larger equity funding channel to support its clinical-stage buildout, but no new cash was raised in this filing. It is modestly supportive for liquidity flexibility and equally clear about the continuing dilution and capital-need overhang.